# Sino Biological

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sino-biological

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: http://www.sinobiological.com
- Total disclosed funding: $29M
- Latest round: Series B (Jan 23, 2020)
- Investors on record: 3

## About

Established in 2016 and based in Beijing, China, Sino Biological Inc. operates as a contract research organization (CRO) service provider that focuses on biotechnology. The company has 330 employees and 33% of the core research team has master's degree. The founder, Dr. Liangzhi Xie has undertaken a number of national "863" program, and the national "new drug creation" major special projects. In April 2016, the company's product, SCT400, entered the clinical phase III.

Sino Biological provides the R&D, production, sales and technology of biological reagent and pre-clinical scale production service for pharmaceutical company or biotech company. The product of the company includes recombinant protein, antibody, gene and culture medium, such as IL-1 beta primes innate immunity, CD155 and its receptors and common humancoronavirus(HCoV) antigens. The CRO service of the company includes recombinant protein and antibody development and biological analysis and detection. Sino Biological adopts quality control system, such as molecular level testing, basic physical and chemical testing, multiple immunological testing.

## Funding rounds

- Series B, Jan 23, 2020 — Tsing Song Capital, Nanli Capital
- Series A, Jul 6, 2017, $29M — Qiming Venture Partners

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A
- Tsing Song Capital (https://capitalatlas.ai/funds/tsing-song-capital) — Series B
- Nanli Capital (https://capitalatlas.ai/funds/nanli-capital) — Series B